Skip to main content

RX Updates

Mechanism of Action of an Interleukin (IL)–23 Inhibitor Monoclonal Antibody in Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis

Sponsored by Janssen Biotech, Inc.
This disease education update from Janssen provides an overview of an interleukin (IL)-23 inhibitor.

Disease Modification in Lupus and Lupus Nephritis: Modifying the Natural Course of the Disease

Sponsored by GSK US Medical Affairs
Discover how you can apply the concept of disease modification in lupus and lupus nephritis to help treat patients in your clinical practice. View our infographic and walk through an interactive patient journey towards disease modification. Also, listen to leading expert Dr. Michelle Petri to learn about scientific advances in monitoring for renal damage accrual in lupus nephritis.

Heart to Heart: Experts Discuss Cardiovascular Risk in Rheumatoid Arthritis

Sponsored by AbbVie Medical Affairs
Tune in as rheumatologists Dr. Christina Charles-Schoeman and Dr. Roy Fleischmann discuss how you can help mitigate cardiovascular risk in your patients with rheumatoid arthritis.

Women in Rheumatology: The XX Factor

Sponsored by Bristol Myers Squibb
Nine videos discussing gender differences in axSpA, PsA, Vasculitis, Lung Disease, Osteoporosis, Disparities in Healthcare, and Rheumatologic Activity and Treatment, are now available.

Biologics in Lupus - Why, Who and When?

Sponsored by GSK US Medical Affairs
Leading experts from the SLE Educators’ Network discuss how biologic therapies may help address key unmet needs in lupus, while highlighting how clinicians can identify the most appropriate patients for biologic treatment.

A JAK Inhibitor for nr-axSpA

Sponsored by AbbVie Medical Affairs
Read for an overview of Week 14 efficacy and safety data with JAK inhibitor treatment in patients with nr-axSpA, and hear about Dr. Nimesh Dayal’s perspective on the relevance of clinical trial measures in clinical practice.

Perspectives on the Safety of a JAK Inhibitor

Sponsored by AbbVie Medical Affairs
Addressing rheumatology patients’ needs: Drs. Pendleton Wickersham, Kevin Winthrop, and Christopher Ritchlin discuss benefit-risk of a JAK inhibitor in patients with RA, PsA, and AS. Long-term safety clinical trial data is also presented.

A Rheum & Derm Perspective on Treating PsA and Moderate-to-Severe PsO

Sponsored by Lilly USA
Dr. Mease and Dr. Armstrong discuss a multidisciplinary approach and important considerations when treating patients with joint and skin concerns. Ages 18+; for HCPs only.

Long-term JAK Inhibitor Treatment for Rheumatoid Arthritis (RA)

Sponsored by AbbVie Medical Affairs
Addressing RA patients’ needs: Dr. Len Calabrese discusses how to talk about treatment goals and benefit-risk with RA patients. Also, explore the long-term Phase 3 clinical trial data for a JAK inhibitor.

JAK Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response or Intolerance to TNF Inhibitors (TNFi-IR)

Sponsored by AbbVie Medical Affairs
Read for an overview of post hoc subgroup analysis results from TNF-IR RA patients in SELECT BEYOND, COMPARE, and CHOICE clinical trials of upadacitinib in RA patients…

Solving Still's Disease

Dr. Jack Cush reviews the history, manifestations, diagnosis and treatment of Still's disease.

Long-term JAK Inhibitor Treatment for Psoriatic Arthritis (PsA)

Sponsored by AbbVie Medical Affairs
Read for an overview of long-term results from SELECT-PsA 2, a clinical trial of oral upadacitinib vs. placebo in bDMARD-refractory PsA patients.